After-Hours Stock Movers

TAT Technologies (NASDAQ: TATT) 121.3% HIGHER; TAT and Honeywell International, Inc., (NYSE: HON) announced today a 10-year agreement to support the global MRO activities for the GTCP331-200/250 auxiliary power unit (the “331 APU”).

GENFIT (NASDAQ: GNFT) 12.8% HIGHER; announced the first patient first visit for ELATIVE, the global, pivotal, Phase 3 study evaluating elafibranor in Primary Biliary Cholangitis (PBC).

Luminex Corporation (NASDAQ: LMNX) 6.7% HIGHER; received a $5,389,813 award from the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response within the U.S. Department of Health and Human Services, to conduct product development work and complete a 510(k) filing for Luminex's expanded NxTAG® Respiratory Pathogen Panel (RPP), which includes the SARS-CoV-2 virus for high-throughput COVID-19 testing. This effort will help address the continuing long-term need for cost-effective, multiplex diagnostic tests that can differentiate COVID-19 from current strains of other common respiratory illnesses, such as flu.

Novavax, Inc. (Nasdaq: NVAX) 6.4% HIGHER; initiated its first Phase 3 study to evaluate the efficacy, safety and immunogenicity of NVX-CoV2373, Novavax COVID-19 vaccine candidate. The trial is being conducted in the United Kingdom (UK), in partnership with the UK Governments Vaccines Taskforce, and is expected to enroll and immunize up to 10,000 individuals between 18-84 (inclusive) years of age, with and without relevant comorbidities, over the next four to six weeks.

IBEX Limited (NASDAQ: IBEX) 4.2% LOWER; reported Q4 EPS of $0.14, $0.02 worse than the analyst estimate of $0.16. Revenue for the quarter came in at $100.9 million versus the consensus estimate of $96.24 million.

Costco (NASDAQ: COST) 2.7% LOWER; reported Q4 EPS of $3.13, $0.30 better than the analyst estimate of $2.83. Revenue for the quarter came in at $53.38 billion versus the consensus estimate of $52.08 billion. Total company comps in the quarter rose 11.4% or 14.1% adjusted. e-Commerce comps rose 90.6% or 91.3% adjusted.

Bristol Myers Squibb (NYSE: BMY) 1.2% HIGHER; today announced that CheckMate -274, a pivotal Phase 3 trial evaluating Opdivo (nivolumab) after surgery in patients with high-risk, muscle-invasive urothelial carcinoma, met its primary endpoints of improving disease-free survival (DFS) versus placebo in both all randomized patients and in patients whose tumor cells express PD-L1 1% (programmed death-ligand 1). CheckMate -274 is the first and only Phase 3 trial in which immunotherapy has reduced the risk of relapse in the adjuvant setting for these patients. The safety profile of Opdivo was consistent with previously reported studies in solid tumors.

Vail Resorts (NYSE: MTN) 1.2% HIGHER; reported Q4 EPS of ($3.82), $0.39 worse than the analyst estimate of ($3.43). Revenue for the quarter came in at $77.21 million versus the consensus estimate of $140.94 million.

Calamp Corp. (NASDAQ: CAMP) 1.2% HIGHER; reported Q2 EPS of ($0.03), $0.03 worse than the analyst estimate of $0.00. Revenue for the quarter came in at $83.5 million versus the consensus estimate of $76.84 million.